MiR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin

Oncogene

Volumn 35, Issue 3, 2016, Pages 323-332

  Zhu, X ^a,b   Shen, H ^b,c   Yin, X ^a   Long, L ^a   Xie, C ^b   Liu, Y ^a   Hui, L ^b   Lin, X ^a   Fang, Y ^c   Cao, Y ^b   Xu, Y ^a   Li, M ^a   Xu, W ^a   Li, Y ^a  

^a The Fourth Affiliated Hospital of Jiangsu University   (China)

^b JIANGSU UNIVERSITY   (China)

^c AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MICRORNA; MIRN186 MICRORNA, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CANCER STAGING; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MIDDLE AGED; MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; TWIST TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955643085     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.84     Document Type: Article

References (38)

1. Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst 2014; 106: pii: dju249.
2. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-516.
3. Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY et al. Epithelialmesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med 2014; 6: 1279-1293.
4. Gardi NL, Deshpande TU, Kamble SC, Budhe SR, Bapat SA. Discrete molecular classes of ovarian cancer suggestive of unique mechanisms of transformation and metastases. Clin Cancer Res 2014; 20: 87-99.
5. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014; 16: 488-494.
6. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M et al. An epithelialmesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013; 19: 279-290.
7. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-5828.
8. Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP et al. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene 2015; 34: 1899-1907.
9. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009; 69: 2400-2407.
10. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006; 12: 4147-4153.
11. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 2006; 118: 290-301.
12. Jia L, Zhang S, Ye Y, Li X, Mercado-Uribe I, Bast RC Jr. et al. Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblastlike cells. Cancer Lett 2012; 326: 176-182.
13. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer cell 2013; 23: 186-199.
14. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
15. Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol 2011; 121: 200-205.
16. Parikh A, Lee C, Peronne J, Marchini S, Baccarini A, Kolev V et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun 2014; 5: 2977.
17. Nuti SV, Mor G, Li P, Yin G. TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis. Oncotarget 2014; 5: 7260-7271.
18. Qin Q, Xu Y, He T, Qin C, Xu J. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res 2012; 22: 90-106.
19. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 2009; 15: 2657-2665.
20. Hosono S, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A et al. Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer 2007; 96: 314-320.
21. Li J, Wood WH 3rd, Becker KG, Weeraratna AT, Morin PJ. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene 2007; 26: 2860-2872.
22. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005; 65: 5153-5162.
23. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999; 13: 2207-2217.
24. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 2012; 31: 2521-2534.
25. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010; 12: 982-992.
26. Sun C, Li N, Yang Z, Zhou B, He Y, Weng D et al. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst 2013; 105: 1750-1758.
27. Baribeau S, Chaudhry P, Parent S, Asselin E. Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines. PLoS One 2014; 9: e86987.
28. Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 2012; 22: 194-207.
29. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
30. Chen D, Sun Y, Yuan Y, Han Z, Zhang P, Zhang J et al. miR-100 induces epithelialmesenchymal transition but suppresses tumorigenesis, migration and invasion. PLoS Genet 2014; 10: e1004177.
31. Erdmann K, Kaulke K, Thomae C, Huebner D, Sergon M, Froehner M et al. Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs. BMC Cancer 2014; 14: 82.
32. Cai J, Wu J, Zhang H, Fang L, Huang Y, Yang Y et al. miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res 2013; 73: 756-766.
33. Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, Neukam FW et al. miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep 2014; 31: 1429-1436.
34. Goeppert B, Schmezer P, Dutruel C, Oakes C, Renner M, Breinig M et al. Down-regulation of tumor suppressor A kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms. Hepatology 2010; 52: 2023-2033.
35. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 2010; 70: 367-377.
36. Farrand L, Byun S, Kim JY, Im-Aram A, Lee J, Lim S et al. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. J Biol Chem 2013; 288: 23740-23750.
37. Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer 2014; 135: 1286-1296.
38. Zhu X, Li Y, Shen H, Li H, Long L, Hui L et al. miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Lett 2013; 587: 73-81.